RxDoctor Payments Data

Barbara Depa

Psychiatric/Mental Health · San Antonio, TXNPI 1063135374

Payments from drug & device makers

$2,178in general payments, 2019–2025

Across 135 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$395
  • Teva Pharmaceuticals USA, Inc.$375
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$341
  • AbbVie$273
  • E.r. Squibb & Sons, L.L.C.$175
  • Otsuka America Pharmaceutical, Inc.$148
  • plus $471 from 7 others

What the payments were for

  • Food & beverage$2,02393%
  • Education$1557%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,178 in reported general payments places this provider in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$8,234
Medicare patients
54
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate98$289,519
Invega TrinzaPaliperidone Palmitate16$164,979
IngrezzaValbenazine Tosylate18$149,768
Abilify MaintenaAripiprazole51$143,987
UzedyRisperidone23$78,305
AristadaAripiprazole Lauroxil15$47,983
VraylarCariprazine Hcl24$38,403
Lurasidone Hcl43$7,137
Aripiprazole114$5,404
Hydroxyzine Hcl146$3,303
Clozapine36$3,222
Haloperidol Decanoate29$2,116
Divalproex Sodium ErDivalproex Sodium47$1,945
Bupropion XlBupropion Hcl99$1,778
Duloxetine Hcl87$1,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$59$454,498114 claims
Neurocrine Biosciences, Inc.Ingrezza$113$149,76818 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$148$143,98751 claims
Teva Pharmaceuticals USA, Inc.Uzedy$375$78,30523 claims
Alkermes, Inc.Aristada$395$47,98315 claims
AbbVieVraylar$273$38,40324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →